Clinical Trials in Oncology

Jacob Fleming Conferences16-17 September 2010, Budapest, Hungary.
Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide, with rising research, treatment and commercial importance. Carefully designed and efficiently conducted clinical trial can deliver new oncology drugs and diagnostics to the marketplace. There is a number of challenges in this area which remain; specifically regarding patient recruitment and regulatory issues.

Attend to explore effective patient recruitment and enrollment strategies and understand regulatory considerations surrounding clinical trials in oncology. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on conducting clinical trials in emerging markets in CEE, APAC and India.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from the pharmaceutical industry as well as from the oncology-focused institutions and organizations. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Vice President, Chief Clinical Officer, Teva, Israel
  • Global Clinical Operations Head Oncology, Johnson & Johnson, UK
  • Chief Medical Officer, Kiadis Pharma, The Netherlands
  • Group Head Clinical Project Management, Pfizer, Germany
  • Clinical Trials Consultant to MHRA, UK
  • Clinical Trial Head, Novartis, Switzerland
  • CRUK Professor of Translational Cancer Research, University of Glasgow, UK
  • Director Clinical Research Internal Medicine Early Stage Development, Merck Sharp & Dohme, The Netherlands
  • Principal Clinical Development Scientist, GlaxoSmithKline, UK
  • Executive Director, Oncology Global Development and Medical Affairs, Bristol Myers Squibb, France
  • Group Leader Global Clinical Development Unit Oncology, MerckSerono, Germany

Key topics:

  • Recruitment and enrollment in clinical trials. Expectations and reality.
  • Current regulatory situation in relation to clinical trials in the EU
  • Biomarkers as valuable decision making tools in clinical drug development
  • How are Pharma companies implementing and managing adaptive clinical trial
  • Challenges and opportunities of conducting clinical trials in Emerging Markets

Who should attend:
Vice presidents, Global heads, Heads, Directors, Senior managers, Managers within pharmaceutical companies and oncology-focused institutions and organizations responsible for: Oncology, Clinical research and Development, Clinical trials, Clinical operations, Medical affairs, Drug development and research, Biomarkers, Imaging.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/clinical-trials-in-oncology

About the Jacob Fleming Conferences
Jacob Fleming Conferences have always been carefully designed to provide key strategic business information and the best networking opportunities for the participants. This young, dynamically growing company provides events for specialized industries including Finance, Life Science, Telecommunications, Chemical, and cross industry sectors. Extensive research, targeted speaker selection and top class venues provide a unique incentive and exceptional opportunities for the executives and experts participating in Jacob Fleming conferences. For more information, visit www.jacobfleming.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]